


HEALTH SERVICES 2021



BioNexus Gene Lab Corp Rank 21 of 79





HEALTH SERVICES 2021



BioNexus Gene Lab Corp Rank 21 of 79

The relative strengths and weaknesses of BioNexus Gene Lab Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioNexus Gene Lab Corp compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 100% points. The greatest weakness of BioNexus Gene Lab Corp is the variable Cost of Goods and Services Sold, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is 191%, being 148% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	7,985
Assets, Non-Current	2,130
Cost of Goods and Services Sold	9,671
Depreciation, Depletion, Amortization	0
General and Administrative Expense	1,333
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	3,374
Long Term Liabilities	80
Operating Costs and Expenses	0
Other Assets	-1,786
Other Compr. Net Income	151
Other Expenses	0
Other Liabilities	0
Other Net Income	-157
Other Revenues	12,277
Property Plant and Equipment	1,786
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	10,115
Liabilities	3,453
Expenses	11,004
Revenues	12,277
Stockholders Equity	6,662
Net Income	1,117
Comprehensive Net Income	1,268
Economic Capital Ratio	191%

